Clearstead Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Clearstead Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$308	Buy	+73	New	+$281	﹤0.01%	3067
2026 Q1	–	Sell	-41	Closed	-$139	–	2552
2025 Q4	$139	Sell	41 -2,987	-99%	-$7.76K	﹤0.01%	2470
2025 Q3	$3.97K	Buy	3,028 +1,513	+100%	+$1.57K	﹤0.01%	2247
2025 Q2	$1.09K	Buy	+1,515	New	+$1.19K	﹤0.01%	2422
2023 Q4	–	Sell	-20,000	Closed	-$193K	–	1569
2023 Q3	$193K	Hold	20,000	–	–	0.01%	435
2023 Q2	$213K	Buy	+20,000	New	+$215K	0.01%	423

Other funds holding IRWD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Clearstead Advisors's IRWD Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Ironwood Pharmaceuticals (IRWD) in Q2 2026: 73 shares worth $308. The stake represents ﹤0.01% of the portfolio and ranks #3067 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in IRWD as recently as Q4 2025.

Clearstead Advisors first reported a position in IRWD in Q2 2023 and has held it in 6 quarters since. The position peaked at $213K in Q2 2023. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

Clearstead Advisors held 73 shares of Ironwood Pharmaceuticals worth $308 as of Q2 2026.
Ironwood Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
Ironwood Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3067 holding.
Clearstead Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
Clearstead Advisors's Ironwood Pharmaceuticals position peaked at $213K in Q2 2023.
212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.